Ranibizumab Treatment for Age-Related Macular Degeneretion
NCT ID: NCT02158624
Last Updated: 2014-06-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2013-12-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.
NCT02321839
Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration
NCT02328209
Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
NCT00284089
Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration.
NCT01831947
Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
NCT01948830
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ranibizumab
Intravitreal Lucentis 0.5mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intravitreal Lucentis 0.5mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects of either gender age 50 years or older
* Visual acuity better than 0.05 decimal( 20/400 Snellen)
* Signed informed consent form
Exclusion Criteria
* Patients whose lesion site evaluated by FA examination is more than 12DA in subject eye
* Patients with treatment of triamcinolone intravitreal injection within 6 months in subject eye
* Patients with a history of intraocular surgical operation(including cataract)within 3 months in subject eye
* Patients with serious allergic history to such as fluorescein, indocyanine green, iodophors
* The pregnant or lactating woman
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Occupational and Environmental Health
OTHER
Kurume University
OTHER
Fukuoka University
OTHER
Clinical Research Support Center Kyush
OTHER
Novartis
INDUSTRY
Kyushu University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yuji Oshima
Assistant professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Ophthalmology, Kyushu University Hospital
Maidashi, Higashiku, Fukuoka-city, Fukuoka, Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-E-09
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.